Market News Archives

Reverse Merger, Forward Thinking: InMed, Mentari and the Billion‑Patient Migraine Market -( $INM )

by John F. Heerdink, Jr. May 19, 2026 368Views 0Likes

InMed Pharmaceuticals’ (NASDAQ: INM) planned merger with Mentari Therapeutics reads less like a struggling micro-cap pivot and more like a biotech coming‑of‑age story set against a trillion‑dollar headache: migraine. If the deal closes as outlined, a once‑overlooked cannabinoid platform could become the…

Not Another AI Toy: How Commure Built a $6 Billion Healthcare Workhorse

by John F. Heerdink, Jr. May 19, 2026 377Views 0Likes

Commure’s latest funding round reads less like a startup press release and more like a subtle reset for how Wall Street thinks about AI in healthcare—less science project, more infrastructure play with real revenue attached. A $6 Billion Reminder That Healthcare Runs…

Eupraxia, Dupixent, and the Race to Redefine EoE Care -( $EPRX $REGN $SNY )

by John F. Heerdink, Jr. May 18, 2026 467Views 0Likes

Eupraxia’s (NASDAQ: EPRX) current analyst chorus post their most recent First Quarter 2026 Financial Results report is now singing from the same hymn book: this is a late-stage GI platform story with cash in the bank, near-term catalysts, and price targets that…

May 18, 2026 – War Headlines, $100 Oil & NVIDIA: Why Your Portfolio Is More Nervous Than You Are -( $AMWL $DAL $GOVX $HD $INTG $JNJ $M $MCD $MODD $MRK $SOAR $TGT $WMT Rise!)

by John F. Heerdink, Jr. May 18, 2026 8439Views 0Likes

US stocks traded choppy on Monday, May 18, 2026, as investors balanced war headlines, rising oil, and anticipation for Nvidia’s mid‑week earnings, with indexes hovering near recent records while breadth and small caps lagged. Bond yields eased after last week’s spike, even…

Amwell, Meet Mother Nature: Why Virtual Care May Thrive on Real‑World Green Space -( $AMWL )

by John F. Heerdink, Jr. May 18, 2026 301Views 0Likes

In a world where investors handicap everything from rate cuts to chip cycles, a quieter thesis is gaining traction: exposure to actual trees may be as material to human performance as exposure to Treasury yields. A growing body of research in leading…

From Mortgage Pains to Rocket Gains: What Homebuilders, Oil, and SpaceX Mean for Your Portfolio

by John F. Heerdink, Jr. May 18, 2026 377Views 0Likes

U.S. markets woke up to a strangely reassuring mix of higher builder cheer, pricier crude, a firmer dollar, and a rocket company doing what rockets do best—splitting the atmosphere, and now, its stock. Housing: Confidence Rises, Affordability Still Bites Homebuilder sentiment has…

From Viral Load to Order Book: What the Congo Ebola Outbreak Could Mean for Vaccine Names -( $MRK $JNJ $GOVX )

by John F. Heerdink, Jr. May 18, 2026 392Views 0Likes

A new Ebola outbreak in Congo is once again testing global health systems, but it is also spotlighting a small group of vaccine developers who have spent the quiet years preparing for noisy ones like this. As health agencies scramble on the…

K‑Shaped America: Strong Homeowners, Stressed Shoppers, and Bond Markets on a Caffeine High -( $MCD $WHR $TLT )

by John F. Heerdink, Jr. May 18, 2026 337Views 0Likes

America’s economy is starting to look like the letter K drawn by an urban planner: straight lines for the haves, sharp angles for the have‑nots, and a few confused arrows in between. At the center of the story are homeowners, shoppers, and…

China’s $17 Billion Grocery Run: How Commodities, Conflict, And Chips Are Repricing The World -( $AMD $CMG $GLW $INTC $MCD $NVDA $QSR $WMT )

by John F. Heerdink, Jr. May 17, 2026 442Views 0Likes

The global economy is serving up a curious 2026 prix fixe: China shopping for U.S. commodities again, CEOs quietly hiking menu prices, tankers dodging tension near Hormuz, and Nvidia (NVDA) back on investors’ dessert tray as “flavor of the day.” China’s…

FDA Musical Chairs: What the Latest Leadership Shuffle Means for Biotech Investors -( $IBB $XBI )

by John F. Heerdink, Jr. May 16, 2026 431Views 0Likes

The FDA’s latest reshuffle of its top drug and biologics leaders lands biotech in yet another plot twist—but this one may read more like a quirky chapter break than a full-blown cliffhanger for investors. FDA’s New Cast at the Top The Food…

Market News

Your Guide To Staying Informed In The Markets